Wellmind Health: Digital Health Treatments and Development

Wellmind Health’s proprietary cloud-based Digital Treatments as a Service (DTaaS) platform is designed exclusively for scalable development, deployment and delivery of digital treatments, with real-time patient and clinical data available through a unique management portal that delivers best-in-class functionality and world-leading clinical data. In use in hospital and clinic settings, our clinical-grade treatments for better mental health and pain management deliver long-term improved health outcomes, health system benefits and in-year cost savings with full healthcare regulatory compliance.

Operating in the UK and the US, Wellmind Health has transformed the lives of over 16,000 patients, is deployed across over twenty NHS Trusts and in the private sector for clients such as Circle Health and Crossroads, USA.

Thei drug-free digital therapeutic treatments significantly reduce stress, anxiety and depression and dramatically improve the self-management of chronic pain. Flexible and accessible, their clinical-grade programs have guided many thousands of patients to long-term improved health and wellbeing outcomes.

Clinicians and therapists can manage patients, monitor engagement and satisfaction in real time, and report on their self-assessed health outcomes using a variety of clinical outcome measurements at granular and aggregated levels. As well as general depression, stress, anxiety and chronic pain, programs are also employed in the research and treatment of specific patient groups, such as pregnant women, recovering fentanyl and opioid addicts and autistic adults.

Wellmind Health are delighted to join this established platform for healthcare stakeholders, including providers, policymakers, industry partners, and innovators, to connect and collaborate. They look forward to knowledge sharing and supporting the facilitation of best practices, insights, and knowledge related to connected health and digital health solutions in particular digital therapeutic treatments. They are also excited to engage in Market Access opportunities, where we believe ECHA can support us to expand our reach beyond our local and national parameters. Specifically, they are excited to explore Research and Innovation Support opportunities that may be afforded to us through association with the ECH. They are keen to explore collaboration opportunities with research institutions and organizations that can support us with research into this novel area of health technology advancement.